Paradigm Biocapital Advisors LP Tarsus Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.67 Billion
- Q1 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,863,406 shares of TARS stock, worth $77.8 Million. This represents 3.9% of its overall portfolio holdings.
Number of Shares
2,863,406
Previous 1,025,000
179.36%
Holding current value
$77.8 Million
Previous $20.8 Million
401.46%
% of portfolio
3.9%
Previous 1.08%
Shares
2 transactions
Others Institutions Holding TARS
# of Institutions
166Shares Held
39.5MCall Options Held
190KPut Options Held
92.9K-
Rtw Investments, LP New York, NY3.27MShares$88.9 Million1.91% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$72.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.4MShares$65.2 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$61.3 Million9.98% of portfolio
-
Cormorant Asset Management, LP Boston, MA2.14MShares$58.1 Million4.48% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $725M
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...